Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 15/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4363886 | 0.86 | NPC1 (0.78) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL14096025 | 0.85 | MAPT (0.73) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL4365149 | 0.81 | MAPT (0.65) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL14096020 | 0.80 | ALDH1A1 (0.75) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4361501 | 0.78 | MAPT (0.72) | MAPTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL4364686 | 0.78 | ALDH1A1 (0.72) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL14096016 | 0.77 | MAPT (0.74) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL7822012 | 0.77 | ALDH1A1 (0.76) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL14096475 | 0.77 | MAPT (0.70) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL5450484 | 0.77 | MAPT (0.74) | MAPTALDH1A1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | MAPT 4038/4885ALDH1A1 2930/4885MEN1 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.